Warning! GuruFocus detected
1 Severe warning sign
with ANTX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
AN2 Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0373261058
Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.89 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -15.4 | |||||
| 3-Year EPS without NRI Growth Rate | -11.5 | |||||
| 3-Year FCF Growth Rate | -13.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.23 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.08 | |||||
| 9-Day RSI | 58.48 | |||||
| 14-Day RSI | 61.69 | |||||
| 3-1 Month Momentum % | -22.92 | |||||
| 6-1 Month Momentum % | 4.72 | |||||
| 12-1 Month Momentum % | -65.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.43 | |||||
| Quick Ratio | 8.43 | |||||
| Cash Ratio | 8.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -51 | |||||
| ROA % | -45.97 | |||||
| ROIC % | -502.29 | |||||
| 3-Year ROIIC % | -1534.67 | |||||
| ROCE % | -54.21 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.53 | |||||
| Price-to-Tangible-Book | 0.53 | |||||
| EV-to-EBIT | 0.91 | |||||
| EV-to-EBITDA | 0.91 | |||||
| EV-to-FCF | 1 | |||||
| Price-to-Net-Current-Asset-Value | 0.57 | |||||
| Price-to-Net-Cash | 0.59 | |||||
| Earnings Yield (Greenblatt) % | 109.89 | |||||
| FCF Yield % | -113.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
AN2 Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.72 | ||
| Beta | 0.14 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 93.4 | ||
| 14-Day RSI | 61.69 | ||
| 14-Day ATR ($) | 0.068522 | ||
| 20-Day SMA ($) | 1.36375 | ||
| 12-1 Month Momentum % | -65.53 | ||
| 52-Week Range ($) | 0.87 - 3.88 | ||
| Shares Outstanding (Mil) | 30.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AN2 Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AN2 Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AN2 Therapeutics Inc Frequently Asked Questions
What is AN2 Therapeutics Inc(ANTX)'s stock price today?
The current price of ANTX is $1.44. The 52 week high of ANTX is $3.88 and 52 week low is $0.87.
When is next earnings date of AN2 Therapeutics Inc(ANTX)?
The next earnings date of AN2 Therapeutics Inc(ANTX) is 2025-03-28 Est..
Does AN2 Therapeutics Inc(ANTX) pay dividends? If so, how much?
AN2 Therapeutics Inc(ANTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers